BRIEF COMMUNICATION

Seronegative antibody-mediated neurology after immune checkpoint inhibitors

Robert Wilson1, David A. Menassa1, Alexander J. Davies1, Sophia Michael1, Joanna Hester2, Wilhelm Kuker3, Graham P. Collins4, Judith Cossins1, David Beeson1, Neil Steven5, Paul Maddison6, Simon Rinaldi1, Saiju Jacob7 & Sarosh R. Irani1

1Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
2Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
3Neuroradiology Department, Oxford University Hospitals, Oxford, United Kingdom
4Department of Clinical Haematology, Churchill Hospital, Oxford, United Kingdom
5Department of Clinical Oncology, University Hospitals Birmingham, Birmingham, United Kingdom
6Department of Neurology, Queen’s Medical Centre, Nottingham, United Kingdom
7Centre for Rare Diseases and Queen Elizabeth Neuroscience Centre, University Hospitals Birmingham, Birmingham, United Kingdom

Correspondence
Prof Sarosh R. Irani, West Wing, Level 3, John Radcliffe Hospital, Oxford OX3 9DU.
Tel: +44(0)1865 234531; Fax: +44(0)1865 234699; E-mail: sarosh.irani@ndcn.ox.ac.uk

Funding Information
SRI is supported by the Wellcome Trust (104079/Z/14/Z), BMA Research Grants – 2013 Vera Down grant and Margaret Temple Grant 2017, Epilepsy Research UK (P1201), and by the Fulbright UK-US commission (MS-Research Society Award). SR is supported by the Medical Research Council (MR/P008399/1). JC and DB supported by MRC Programme Grant MR/M006824. JH is supported by KRUK. The research was funded/supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC; The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health).

Received: 6 September 2017; Revised: 26 January 2018; Accepted: 12 February 2018

Abstract

Checkpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune-related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody-mediated neurological diseases after checkpoint inhibitors: longitudinally extensive transverse myelitis, Guillain–Barré/C19e syndrome, and myasthenia gravis. All patients shared three characteristics: symptoms commenced 4 weeks after drug administration, responses to conventional immunotherapies were excellent, and autoantibodies traditionally associated with their syndrome were absent. However, serum immunoglobulins from the myelitis and Guillain–Barré syndrome patients showed novel patterns of tissue reactivity. Vigilance is required for antibody-mediated neurology after checkpoint inhibitor administration. This phenomenon may inform the immunobiology of antibody-mediated diseases.

Introduction

A major recent advance in oncology has been the success of immune checkpoint inhibitors. These drugs are increasingly used to treat various cancers including melanoma, kidney adenocarcinoma, lung carcinomas, and hematological malignancies.1 They commonly target programmed death 1 (PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) and, more rarely, PD-ligand 1 (PD-L1). PD-1, and CTLA-4 are expressed in both conventional T cells and regulatory T cells (Tregs), among other cell types.2,3 However, immune-related adverse events (irAEs) affect up to 40% of patients treated with checkpoint inhibitors and include colitis, dermatitis, pneumonitis, and hepatitis.4
More rarely, neurological side effects are observed: the most frequent is hypophysitis. While conventional models typically suggest irAEs are T cell mediated, here, we describe likely antibody-mediated autoimmunity with the first case of immune checkpoint-blockade associated with longitudinally extensive transverse myelitis (LETM, n = 1), and cases who developed myasthenia gravis (MG, n = 2) and Guillain–Barré syndrome (GBS, n = 1) after checkpoint inhibitors. The escalating use of these drugs in oncology requires heightened vigilance among neurologists for these associated, often seronegative, autoantibody-mediated side effects that respond well to conventional immunotherapies.

**Patients and Methods**

Four patients prospectively observed during routine Autoimmune Neurology practice between July 2015 and March 2017 administered immune checkpoint inhibitors are summarized in Table 1. We performed blinded testing of serum for autoantibodies in all patients, almost exclusively using previously described live cell-based assay methodologies (Table 1), and flow cytometry from whole blood in patient 1. Written informed consent was obtained with ethical approval (REC16/YH/0013).

**Results**

**Clinical features**

Patient 1 was a 35-year-old male diagnosed in 2005 with stage IIa Hodgkin lymphoma which relapsed despite three lines of chemotherapy over 10 years (Table 1). Residual metastases prompted initiation of pembrolizumab (a humanized PD-1 monoclonal antibody) as fourth line

| Table 1. Clinical and investigation features of patients with neurological complications after checkpoint inhibitors. |
|---------------------------------|---------------------|------------------|------------------|------------------|
| Age | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| 35 | Male | Classical Hodgkin lymphoma | Pembrolizumab | 4 weeks |
| 57 | Male | Melanoma | Nivolumab and ipilimumab | 4 weeks |
| 62 | Female | Lung adenocarcinoma | Pembrolizumab | 4 weeks |
| 52 | Male | Melanoma | Nivolumab and ipilimumab | 4 weeks |
| Clinical features | Tetraparesis, sensory level, loss of sphincters | Fatigable ptosis and complex external ophthalmoplegia | Fatigable ptosis and limb weakness | Sensory loss and reduced reflexes |
| Clinical diagnosis | Longitudinally extensive transverse myelitis | Myasthenia gravis | Myasthenia gravis | Guillain–Barré syndrome |
| Novel serum autoantibody? | Yes, IgG | No | No | Yes, IgM |
| Negative antibody results | AQP4, MOG, CRMP5, GFAP, amphiphysin | AChR (including clustered), MuSK, LRP4 | AChR (including clustered), MuSK, LRP4 | Gangliosides, CRMP5, GFAP, Contactin-1, CASPR1, NF140/155/186 |
| Nerve conduction/EMG studies | Not performed | Normal | Normal | Prolonged distal motor latencies, low conduction velocities and absent F waves. |
| Treatment for neurological features | Corticosteroids, intravenous immunoglobulins and plasma exchange | Corticosteroids | Pyridostigmine and corticosteroids | Intravenous immunoglobulins and corticosteroids |
| Oncological Outcome | Complete remission | Death, progression of metastases | Stable lung tumor, resolution of metastases | Reduction in tumor load |
| Neurological Outcome | Excellent, mild residual hypertonia | Complete | Complete | Complete |
| Follow-up period | 2.5 years | 6 months | 1 year | 1 year |

Patient 1 received adriamycin, bleomycin, vinblastine, dacarbazine, then ifosfamide, epirubicin, and etoposide, and finally, brentuximab (CD30 targeting). No relapses of the tumor or neurology were noted. Aquaporin 4 (AQP4) antibodies were not detected on live and fixed cell-based assays. CRMP5 and amphiphysin antibodies were tested by commercial line blot, and GFAP antibodies by fixed cell-based assay. Other antibodies were tested by live cell-based assays. Patient 3 had no single fiber EMG performed, and EMG studies in both patients 2 and 3 were performed after treatment initiation. AChR, acetylcholine receptor; CASPR1, contactin-associated protein 1; CRMP5, collapsin response mediator protein 5; GFAP, glial fibrillary acidic protein; LRP4, low-density lipoprotein receptor-related protein 4; MOG, myelin oligodendrocyte glycoprotein; MuSK, muscle-specific kinase; NF, neurofascin.
therapy, with two cycles given at 3 week intervals. One week after the second cycle, he developed acute urinary retention, constipation, hiccoughs, and vomiting, with weakness and sensory loss in arms and legs. Examination revealed a spastic tetraparesis with profound sensory loss and sphincter atonia. MRI showed a LETM from the pons to the lower thoracic spine with extensive cord edema (Fig. 1A–B). Aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies were not detected. CSF showed 24 mononuclear cells/mm³; other detailed CSF and blood tests were unremarkable (Table S1). Intravenous methylprednisolone and, subsequently, plasma exchange were administered with the aim of depleting free circulating pembrolizumab and any putative autoantibody. During an oral prednisolone taper, repeat MRI at 6 months showed considerable reduction of edema (Fig. 1C–D). One year from symptom onset, he was continent, independent in ambulation, and his Hodgkin lymphoma had responded to the treatment.

To explore the underlying immunology, flow cytometry was performed from the patient’s peripheral blood mononuclear cells at the nadir of the neurological syndrome. This revealed a decrease in Treg numbers (CD3⁺CD4⁺CD25⁺CD127⁺; Fig. 1E–F) and an anti-human-IgG antibody preferentially bound to the residual Tregs that expressed the highest levels of CD62L and CD25, indicating a subpopulation targeted by the humanized pembrolizumab (Fig. 1G–H).

Patient 2 was a 57-year-old male with metastatic melanoma involving the left axilla, mediastinum, and lung hilum. Four weeks after the first infusion of nivolumab (a humanized PD-1 monoclonal antibody; at 1 mg/kg) and ipilimumab (a CTLA-4 blocking antibody; at 3 mg/kg), and 1 week after the second course, he developed exertional breathlessness with diplopia and ptosis which worsened toward the end of the day. Examination showed weak left eye abduction, right eye adduction, and bilateral asymmetrical fatigable ptosis. The remainder of the
examination and investigations were unremarkable. A clinical diagnosis of MG prompted intravenous methylprednisolone followed by 80 mg oral prednisolone, with a rapid improvement in all features. All known MG-associated autoantibodies were negative (Table 1). The corticosteroids were gradually tapered. Patient 3 also developed seronegative MG, with limb weakness and ptosis, 4 weeks after the first dose of pembrolizumab for metastatic lung adenocarcinoma. Complete remission was achieved 3 months after commencing pyridostigmine and corticosteroids.

Patient 4 was a 52-year-old male with metastatic melanoma affecting the ear, cervical lymph nodes, and lung. Treatments included radical neck dissection, and nivolumab with ipilimumab. Three weeks after the first infusion, and 2 days after the second cycle, he developed headache and generalized tiredness. Investigations revealed hypophysitis and prednisolone was commenced. A week later, he experienced progressive hand and feet numbness, with bilateral facial weakness, distal limb weakness, and reduced deep tendon reflexes. CSF was acellular with a protein content of 2.3 g/L. Neuropsychology revealed a demyelinating neuropathy and both whole spine MRI and ganglioside antibodies were unremarkable (Table 1). In summary, the findings were consistent with the acute inflammatory demyelinating polyneuropathy variant of GBS. He was commenced on intravenous immunoglobulins with a very good recovery.

In all four patients, the checkpoint inhibitors were discontinued and no neurological relapses were noted at follow-up (0.5–2.5 years, Table 1).

These 4 cases were observed over a 20 month period, and this exceeded the cumulative frequency of patients with antibodies against dipeptidyl-peptidase-like protein-6 (DPPX, n = 1), the z-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR, n = 0), the gamma-aminobutyric acid A-receptor (GABAAR, n = 1), and IgGn5 (n = 0).8

Novel autoantibody detection

Serum immunoglobulin G exclusively from the patient with LETM bound to rodent brain tissue in a pattern comparable to aquaporin-4 (Fig. 2A–C). In addition, serum immunoglobulin M from the GBS patient, but not the other three patients, bound myelinating cocultured induced pluripotent stem cell-derived sensory neurons and rat primary Schwann cells (Fig. 2D), prepared as previously described.7 These reactivities were not seen in 20 healthy controls. No patient immunoglobulins bound to rodent muscle sections, C2C12 myotubes or CN21 muscle cell lines.

Discussion

Immune checkpoint inhibitors provide an increasingly popular and contemporary approach to effective treatment of many malignancies. This approach increases patient survival but carries risks of irAEs. These complications need to be actively recognized by neurologists in an era with increasing use of these medications in the routine clinical oncology setting, and are likely to be more common than many of the recently described antibody-mediated illnesses.8

The patients we report showed a range of classical antibody-mediated conditions of the central and peripheral nervous system, and shared three intriguing features. First, there was a stereotyped 4-week lag from immune checkpoint inhibitor administration to symptom onset, which has mechanistic implications discussed below. Second, and by contrast to a recent series in MG,10 despite clinical presentations and investigation findings indistinguishable from traditional seropositive equivalents, none showed the common autoantibody profiles associated with their respective conditions. However, two patient sera showed novel autoantibody reactivities with disease-relevant preparations, including one on a live cell system, suggesting study of these patients may hasten the discovery of antigenic targets in conventional antibody-mediated diseases. Finally, all patients showed a very good recovery with symptomatic therapies or immunotherapies including corticosteroids, intravenous immunoglobulins, and/or plasma exchange, without residual clinical deficits or atrophy. This consistent improvement, in addition to the novel observed autoantibody reactivities, suggest antibody-mediated effector neurological mechanisms rather than the more commonly hypothesized checkpoint inhibitor-induced T cell-mediated conditions which affect the skin, gut, and liver.11,12 Indeed, the concept of an autoantibody-mediated condition is supported by the recent discovery of increased plasmablasts,13 and a few organ-specific autoantibodies, post-checkpoint inhibitors.14

In addition to hypophysitis, neurological side effects of the checkpoint inhibitors include very few or single cases of aseptic meningitis, GBS, and myositis.5,13 More recently, 0.1% of patients administered nivolumab were reported to develop MG. Furthermore, multiple sclerosis after CTLA-4 blockade by ipilimumab has been reported in one case where the clonally expanded T cell receptor sequences shared between the CSF and melanoma suggest preformed T cell memory led to the CNS disease.16 Similar close clonal relationships of T cells are recognized between tumor and cardiac tissue in post-checkpoint inhibitor myocarditis,12 supporting the notion that many irAEs are T cell-mediated.

Overall, the consistent 4-week lag observed by us and two cases with autoimmune encephalitis after a similar
interval from immune checkpoint inhibitor administration, suggest insufficient time for generation of a de novo immune response to neurological antigens. More likely, the drug-induced disinhibition of circulating T cells led to the activation of preformed B cell reactivities to neural and neuromuscular proteins. This observation implies that autoantigen-specific T and B cells were circulating in an anergic or quiescent state, contained by Tregs: indeed, flow cytometry from patient 1 suggests the suppressive population were within the CD4+CD25+CD62L+ Tregs bound by the monoclonal antibody pembrolizumab. Interestingly, the presence of preexisting neural antigen-specific cells in those with or without disease may be consistent with the frequent detection of neurological autoantibodies, particularly of the IgM subclass, in healthy control subjects. Similarly, screening of patients without neurological symptoms who have tumors and paraneoplastic autoantibodies, for example, GABA receptor antibodies and small cell lung carcinoma, may identify those with a potentially increased rate of irAEs. As an alternative to a T cell-directed mechanism of action, as PD-1 and CTLA-4 are also expressed on B cells and some myeloid cells, and PD-L1 on neurons and tumor cells, the checkpoint inhibitors may have additional direct actions via other cell types. These mechanisms should be investigated in future studies.

In summary, antibody-mediated neurological complications require increased clinical vigilance given the escalating use of immune checkpoint inhibitors. Further study of these patients may highlight immunological mechanisms operating in all antibody-mediated diseases, and have implications for the detection of anergic autoreactive T and B cells in healthy controls.

Acknowledgments

SRI is supported by the Wellcome Trust (104079/Z/14/Z), BMA Research Grants – 2013 Vera Down grant and Margaret Temple Grant 2017, Epilepsy Research UK (P1201).
and by the Fulbright UK-US commission (MS-Research Society Award). SR is supported by the Medical Research Council (MR/P008399/1). JC and DB supported by MRC Programme Grant MR/M006824. JH is supported by KUUK. The research was funded/supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC; The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health).

**Author Contributions**

RW, AD, JH, DM, JC, DB, WK, PM, SM, SR, GC, and NS were involved in data collection, drafting, and analysis revising manuscript for intellectual content; SJ and SRI were involved in study conceptualization, data collection, drafting, analysis, and revising the manuscript for intellectual content.

**Conflicts of Interest**

GC has received honoraria from Merck and BMS for advisory work and trial funding; SRI receives royalties as a coapplicant on a patent describing VGKC-complex antibodies, including LGI1, CASPR2, and contactin-2, licensed to Euroimmun Ltd.

**References**

1. Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Expert Opin Biol Ther 2017;17:305–312.
2. Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 2017;13:755–763.
3. Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4 + CD25Hi regulatory T cells. Int Immunol 2009;21:1065–1077.
4. Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299–308.
5. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013;13:278–280.
6. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133(Pt 6):1655–1667.
7. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neuro Neurosurg Psychiatry 2016;87:1005–1015.
8. Varley J, Vincent A, Irani SR. Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. J Neurol 2014;262:1081–1095.
9. Clark AJ, Kaller MS, Galindo J, et al. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. Brain 2017;140:898–913.
10. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127–1134. https://doi.org/10.1212/WNL.000000000004359.
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.
12. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755.
13. Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest 2018;128:1–6.
14. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017;28:583–589.
15. Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy. J Neuromuscul Dis 2017;4:169–173.
16. Gerdes LA, Held K, Beltrán E, et al. CTLA4 as an immunological checkpoint in the development of multiple sclerosis. Ann Neurol 2016;80:294–300.
17. Williams TJ, Benavides DR, Patrice K-A, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928–933.
18. Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014;76:82–94.
19. Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology 2015;85:235–239.

**Supporting Information**

Additional Supporting Information may be found online in the supporting information tab for this article:

**Table S1.** Unremarkable investigations in patients. *full* blood count, electrolytes, liver function tests, bone profile; **erythrocyte sedimentation rate, C-reactive protein, antineutrophil cytoplasmic antibodies, antinuclear antibodies; ***Hu, Yo, Ri, CRMP5, glutamic acid decarboxylase, LGI1, CASPR2, MAG, ganglioside screen; ****CMV, EBV, Hepatitis A/B/C, HIV, Borrelia IgMs were negative.